Screening for Diabetic Retinopathy Using AI Instead of Referring to a Specialist
​AEYE Health’s FDA-cleared AI delivers fast, autonomous diabetic retinopathy screening in endocrinology settings. This enables endocrinologists to integrate retinal screening into routine endocrinology care, close care gaps, improve HEDIS scores, and help prevent diabetes-related vision loss.
Advantages of AEYE-DS
_edited.png)
1-minute Screening
Requires only one image per eye; rarely requires dilation; producing instant diagnosis
Practical to operate
Can be operated with a portable handheld camera and a robotic tabletop camera
_edited.png)
Billing and Reimbursement for Diabetic Retinopathy Screening in Primary Care
Reimbursable by Endocrinologists
CPT code 92229 was created for endocrinology providers and covers retinal imaging for the detection or monitoring of diabetic retinopathy, including point-of-care automated analysis and reporting.
Improves HEDIS scores and Star-ratings
Diabetic eye exams performed by endocrinology providers can be reported using CPT Category II codes and counted toward various HEDIS measures, helping practices enhance quality metrics and patient outcomes.
Addresses point-of-care screening payment programs
Screening for diabetic retinopathy addresses MIPS measure 117 and may qualify PCPs for additional payer incentives
Screening prevents blindness
By using AI technology, primary care physicians can screen for diabetic retinopathy on the spot, replacing specialist referrals and closing the diabetic retinopathy care gap.
Our Solution: Point-of-Care Screening
GP visit
On-the-spot diagnosis
Positive
Diabetic retinopathy detected - commence treatment
Negative
Cleared for 12 months
